# KLOW Peptide Results in the Research Literature — Angiogenesis-Vascular Findings > KLOW results in the literature: angiogenesis-vascular findings across BPC-157, GHK-Cu, TB-500 and KPV studies, component by component, with citations. The angiogenesis-vascular findings across the four KLOW components — vessel density, wound closure, VEGFR2 activation, SPARC-derived angiogenic peptides and thymosin beta-4 vascular repair — drawn from peer-reviewed studies. ## In plain English This page collects the angiogenesis (new blood-vessel growth) and vascular repair results across the four KLOW components, which is the research angle this site documents most closely. Angiogenesis is the process by which new blood vessels grow from existing ones — it is essential for wound healing because new vessels deliver the oxygen and nutrients a healing tissue needs. Three of the four KLOW components have documented pro-angiogenic activity in laboratory models. KPV, the anti-inflammatory arm, does not directly drive angiogenesis but reduces the cytokine environment that can impair healing. The combination rationale for KLOW is that these four arms address complementary steps of one process; the gap is that no study has tested them together. KLOW results in the literature, then, means results for each component separately — which is what this page documents. ## BPC-157: VEGFR2-Akt-eNOS angiogenesis pathway The most mechanistically detailed angiogenesis result for BPC-157 is the 2017 Hsieh et al. study: BPC-157 upregulated VEGFR2 (vascular endothelial growth factor receptor 2) expression in human vascular endothelial cells and rat hindlimb ischemia models, promoted VEGFR2 internalization with downstream PI3K/Akt/eNOS pathway activation, increased vessel density in the chick chorioallantoic membrane model, and accelerated blood-flow recovery in ischemic muscle [8]. Effects were blocked by endocytosis inhibition, indicating that receptor internalization is a mechanistically required step. VEGFR2 phosphorylation is the same node that exogenous VEGF activates — BPC-157 approaches it from a different ligand route. Earlier work by Cerovecki and Brcic et al. (2009) directly measured BPC-157's modulatory effect on angiogenesis during muscle and tendon healing in rats, linking the peptide's established tendon-repair outcomes to concurrent enhanced vascularization of the healing tissue [12]. In the 2003 Staresinic et al. transected-Achilles rat study, improved tendon healing across all measured endpoints was accompanied by improved tissue architecture [2] — the angiogenic component of that repair is consistent with the 2017 VEGFR2 mechanism data. ## GHK-Cu: SPARC proteolysis and angiogenic copper-binding peptides The GHK-Cu angiogenesis entry point is biochemically distinct from BPC-157's. The 1994 Lane et al. study demonstrated that proteolysis of SPARC (secreted protein acidic and rich in cysteine, a matrix protein also named osteonectin) releases copper-binding peptides — including GHK and the more potent KGHK — that directly stimulate angiogenesis in endothelial cell assays and in vivo [11]. The angiogenic activity was sequence-specific and did not depend on prior copper loading; this identifies an endogenous SPARC-to-GHK-to-angiogenesis route operating independently of exogenous copper supplementation. In a more recent translational context, Wang et al. (2017) showed GHK-Cu liposomes accelerated scald-wound closure in mice by approximately 14 days and increased HUVEC proliferation by 33.1% versus controls, with upregulated VEGF, FGF-2, CDK4 and CyclinD1 and stronger CD31/Ki67 staining for vascular and proliferative markers [10]. Liposomal encapsulation outperformed free GHK-Cu for angiogenic outcome — a delivery-route finding relevant to the blend-design question of whether different routes change the GHK-Cu angiogenic contribution. ## TB-500 / thymosin beta-4: wound-healing and vascular repair The foundational vascular-repair result for the TB-500 arm is the Malinda et al. 1999 study: in a rat full-thickness wound model, thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, wound contraction by at least 11% by day 7, and raised collagen deposition and angiogenesis — at doses as low as 10 pg for keratinocyte migration stimulation (2–3-fold in vitro) [1]. This is the most-cited single study for TB-500 wound outcomes and describes both the epithelial closure and the vascular component of healing concurrently. Philp et al. (2004) extended this to a multi-endpoint rodent study showing thymosin beta-4 promoting angiogenesis, wound healing and hair-follicle development simultaneously [9], and the 2025 Zhang et al. study demonstrated that Tbeta4-exosome-loaded hemostatic and antibacterial hydrogel improved vascularized wound repair in a model emphasizing the native protein's angiogenic capacity via novel delivery [14]. Sosne et al. (2024) characterized thymosin beta-4's pro-resolving effects via specialized lipid mediators — the mechanism by which the protein resolves rather than merely suppressing inflammation [15]. The TB-500 heptapeptide fragment's own angiogenic data remain less developed than the full-length thymosin beta-4 record; results attributable to one should not be automatically attributed to the other. ## KPV: inflammatory modulation and gut vascular context KPV is not a direct angiogenic agent in the current literature — its mechanism is anti-inflammatory (NF-kappaB and MAPK suppression in epithelial and immune cells), not pro-angiogenic. However, Dalmasso et al. (2008) established that PepT1-mediated KPV uptake reduces intestinal inflammation in both in vitro human epithelial and immune cell models and in DSS/TNBS mouse colitis models [3]. Inflamed mucosa is a hypoxic, pro-angiogenic environment; reducing the inflammatory cytokine load is mechanistically linked to resolution of vascular inflammation. This positions KPV as the anti-inflammatory prerequisite that may improve conditions for the angiogenic arms to operate — though, again, no study has tested this interaction. The connection between KPV's PepT1 uptake and gut vascular biology is also notable: the gut microvasculature is a target of inflammatory cytokines in IBD, and dampening NF-kappaB and MAPK signaling may reduce vascular leak and endothelial activation in inflamed mucosa. These are mechanistic inferences, not experimental findings for the KLOW combination. --- A technical schematic of four separate peer-reviewed literatures — each component dimensioned to its own studies, the untested combination held as the honest blank dimension.